Quince Therapeutics, Inc. QNCX

31.00 1.00 3.33% as of 25 Sep
Market cap
$30.5M
P/E
0.0×
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
4.28 49.82 11.93 8.11 7.85 30.55 8.09 6.05 0.53
Net Debt/EBITDA
0.02 5.77 2.51 1.71 1.19 1.76 2.03 0.63 0.00
Debt/Equity
(0.35) 0.00 0.00 0.00 0.01 0.00 0.16 0.48 (0.50)
ROE
46.25% 47.16% (89.27%) (53.42%) (61.85%) (47.14%) (33.81%) (98.63%) 3,016.49%
ROA
(30.36%) (30.96%) (37.50%) (48.97%) (55.75%) (43.57%) (23.09%) (40.25%) (80.75%)
ROIC
0.00% 0.00% (156.78%) (126.80%) (436.07%) (299.21%) (92.26%) (972.12%) 0.00%
Return on Tangible Assets
(207.51%) (17.47%) (37.78%) (63.36%) (92.05%) (56.72%) (46.09%) (153.29%) 425.53%
Free Cash Flow per Share
(600.24) (708.75) (350.13) (348.66) (424.71) (263.29) (98.61) (148.69) (166.77)
Book value per Share
(1,229.09) (1,942.02) 1,213.00 1,180.69 798.02 600.56 456.95 139.37 (142.57)
Free Cash Flow
(9.90) (11.91) (33.33) (50.87) (63.11) (44.10) (18.36) (32.16) (41.78)
Other line items

Show all line items

Columns are period end dates